Connect Biopharma COPD Study Shows 81% Cut in Treatment FailuresMarketBeat2026. 10. 04. 16:02
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 ProgramInvestorsHub2026. 09. 30. 23:43
BC-Most Active StocksAssociated Press2026. 09. 30. 23:30
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 InflammationGlobeNewswire2026. 09. 30. 20:00
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?Insider Monkey2026. 09. 23. 08:45
Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform RatingMT Newswires2026. 09. 22. 21:50

조회 2026. 10. 12. 00:24 · KST